Medicinal glass is one of the widely used medicinal packaging materials in China. It can be divided into soda lime glass and borosilicate glass. Borosilicate glass is further divided into low borosilicate, medium borosilicate, and high borosilicate glass. According to the "China Pharmaceutical Glass Packaging In-Depth Investigation and Investment Strategy Report (2019 Edition)", at present, domestic medicinal glass products are still dominated by low-borosilicate glass and soda-lime glass.
It is understood that low borosilicate glass is called "semi-neutral borosilicate pharmaceutical glass", which has low chemical stability. When it contains drugs with high pH value, the alkaline substances in the glass are easily precipitated, which affects the quality of drugs. Most countries are no longer using it.
However, in China, most of the medicinal glass is still low borosilicate glass. The total amount of medicinal glass in the whole year is about 300,000 tons, of which the medium borosilicate use data in 2018 is about 22,000 tons. 23,000 tons, according to the proportion, only about 7% to 8%.
As the pharmaceutical packaging industry upstream of the pharmaceutical industry, the market size has maintained a high compound growth rate over the past five years. The Asia-Pacific market, which is driven by China, has overtaken Europe and approached North America in size. However, behind the rapid growth, China's pharmaceutical packaging industry is large but not strong, and the overall added value of the industry is not high. Generally, enterprises are small in scale, low in technology, single in product structure, and in terms of personnel, equipment and management. Large gaps remain.
There is an industry analysis of why China does not produce high-quality, high-qualification medium boron glass tubes. For a long time, high costs have hindered the popularization of neutral pharmaceutical glass in China. In addition, the production stability of medium boron glass tubes is difficult to control. Also hindered the development of neutral medicinal glass to a certain extent.
But medicine is a special kind of commodity, which is directly related to consumers' physical health and life safety. Pharmaceutical packaging materials can directly contact medicines. The quality of medicine packaging materials will affect the safety, stability of medicine properties and the sale of medicines. Speeding up China's upgrade from low-borosilicate glass to medium-borosilicate glass is crucial.
According to the industry, combined with the current Chinese policy and the concept of healthy China, medical packaging is constantly being upgraded, which will vigorously promote the upgrade of low-borosilicate glass to medium-borosilicate glass. According to industry forecasts, in the next 5 to 10 years, 30% -40% of China's 300,000 tons of medicinal glass will be upgraded from low-borosilicate glass to medium-borosilicate glass.
From the perspective of policy implementation, the implementation of important industry policies such as "injection consistency evaluation" and "associated review" will affect the future pattern. The upgrade from low boron to medium boron is still an irreversible trend. "In recent years, China is accelerating policies such as consistency evaluation and related review and approval, which will effectively promote pharmaceutical packaging materials to follow the generic drugs to achieve product upgrades, and the process of replacing neutral medicinal glass is expected to accelerate.